BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15718328)

  • 1. Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions.
    Gasparini G; Longo R; Fanelli M; Teicher BA
    J Clin Oncol; 2005 Feb; 23(6):1295-311. PubMed ID: 15718328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenic inhibitors: a new therapeutic strategy in oncology.
    Gasparini G; Longo R; Toi M; Ferrara N
    Nat Clin Pract Oncol; 2005 Nov; 2(11):562-77. PubMed ID: 16270097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The combination of antiangiogenic therapy with other modalities.
    O'Reilly MS
    Cancer J; 2002; 8 Suppl 1():S89-99. PubMed ID: 12075706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular imaging of antiangiogenic agents.
    Rehman S; Jayson GC
    Oncologist; 2005 Feb; 10(2):92-103. PubMed ID: 15709211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation combined with antiangiogenic and antivascular agents.
    O'Reilly MS
    Semin Radiat Oncol; 2006 Jan; 16(1):45-50. PubMed ID: 16378906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?
    Kerbel RS
    Science; 2006 May; 312(5777):1171-5. PubMed ID: 16728631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
    Cao Y
    Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenesis inhibitors in the management of breast cancer.
    Bossung V; Harbeck N
    Curr Opin Obstet Gynecol; 2010 Feb; 22(1):79-86. PubMed ID: 19952746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined antiangiogenic and immune therapy of prostate cancer.
    Huang X; Raskovalova T; Lokshin A; Krasinskas A; Devlin J; Watkins S; Wolf SF; Gorelik E
    Angiogenesis; 2005; 8(1):13-23. PubMed ID: 16132614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current strategies and future directions of antiangiogenic tumor therapy.
    Zhang ZL; Wang JH; Liu XY
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Oct; 35(10):873-80. PubMed ID: 14515202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interaction of radiation therapy and antiangiogenic therapy.
    O'Reilly MS
    Cancer J; 2008; 14(4):207-13. PubMed ID: 18677126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The present and future of angiogenesis-directed treatments of colorectal cancer.
    O'Dwyer PJ
    Oncologist; 2006 Oct; 11(9):992-8. PubMed ID: 17030640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of angiogenesis in cancer patients.
    Verheul HM; Pinedo HM
    Expert Opin Emerg Drugs; 2005 May; 10(2):403-12. PubMed ID: 15934875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innovative therapies for advanced ovarian cancer.
    Trimble EL
    Semin Oncol; 2000 Jun; 27(3 Suppl 7):24-30. PubMed ID: 10952123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of reoxygenation after antiangiogenic therapy using SU5416 and its importance for guiding combined antitumor therapy.
    Ansiaux R; Baudelet C; Jordan BF; Crokart N; Martinive P; DeWever J; Grégoire V; Feron O; Gallez B
    Cancer Res; 2006 Oct; 66(19):9698-704. PubMed ID: 17018628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy.
    Tonra JR; Hicklin DJ
    Immunol Invest; 2007; 36(1):3-23. PubMed ID: 17190647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.
    Head M; Jameson MB
    Expert Opin Investig Drugs; 2010 Feb; 19(2):295-304. PubMed ID: 20050824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic therapy in nonsmall cell lung cancer.
    Gutierrez M; Giaccone G
    Curr Opin Oncol; 2008 Mar; 20(2):176-82. PubMed ID: 18300767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor angiogenesis in melanoma.
    Marneros AG
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):431-46, vii-viii. PubMed ID: 19464595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic scheduling of lower dose cancer chemotherapy.
    Gately S; Kerbel R
    Cancer J; 2001; 7(5):427-36. PubMed ID: 11693902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.